Sonia Volpi

Verona, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Determinants of early Elexacaftor-Tezacaftor-Ivacaftor use in adults with cystic fibrosis and preserved lung function: insights from a European multicenter survey.

Determinants of early Elexacaftor-Tezacaftor-Ivacaftor use in adults with cystic fibrosis and preserved lung function: insights from a European multicenter survey.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: November 21, 2025

Real-World Safety and Effectiveness of Elexacaftor, Tezacaftor, and Ivacaftor in People with Cystic Fibrosis and Advanced Lung Disease: A Two-Year Multicenter Cohort Study.

Real-World Safety and Effectiveness of Elexacaftor, Tezacaftor, and Ivacaftor in People with Cystic Fibrosis and Advanced Lung Disease: A Two-Year Multicenter Cohort Study.

Journal: International journal of molecular sciences

Published: October 10, 2025

Beyond Trikafta: new models to assess tissue dependent rescue of N1303K-CFTR.

Beyond Trikafta: new models to assess tissue dependent rescue of N1303K-CFTR.

Journal: Frontiers in pharmacology

Published: July 07, 2025

Reported Adverse Events in Patients with CF Receiving Treatment with Elexacaftor/Tezacaftor/Ivacaftor: 5 Years Observational Study.

Reported Adverse Events in Patients with CF Receiving Treatment with Elexacaftor/Tezacaftor/Ivacaftor: 5 Years Observational Study.

Journal: Journal of clinical medicine

Published: April 22, 2025

A Longitudinal Study of Glucose Tolerance in Cystic Fibrosis: The Central Role of Beta Cell Functional Mass.

A Longitudinal Study of Glucose Tolerance in Cystic Fibrosis: The Central Role of Beta Cell Functional Mass.

Journal: The Journal of clinical endocrinology and metabolism

Published: August 24, 2023

Long-term clinical outcomes of elexacaftor/tezacaftor/ivacaftor therapy in adults with cystic fibrosis and advanced pulmonary disease.

Long-term clinical outcomes of elexacaftor/tezacaftor/ivacaftor therapy in adults with cystic fibrosis and advanced pulmonary disease.

Journal: Respiratory medicine

Published: June 12, 2023

Relationship Between Lung Volumes and Heterogeneity in the Response to Elexacaftor/Tezacaftor/Ivacaftor in Patients With Cystic Fibrosis and Advanced Lung Disease.

Relationship Between Lung Volumes and Heterogeneity in the Response to Elexacaftor/Tezacaftor/Ivacaftor in Patients With Cystic Fibrosis and Advanced Lung Disease.

Journal: Chest

Published: May 08, 2023

The non-invasive evaluation of liver involvement in patients with cystic fibrosis: A prospective study.

The non-invasive evaluation of liver involvement in patients with cystic fibrosis: A prospective study.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: May 07, 2023

In silico analysis and theratyping of an ultra-rare CFTR genotype (W57G/A234D) in primary human rectal and nasal epithelial cells.

In silico analysis and theratyping of an ultra-rare CFTR genotype (W57G/A234D) in primary human rectal and nasal epithelial cells.

Journal: iScience

Published: October 03, 2022

Impact of CFTR Modulators on Beta-Cell Function in Children and Young Adults with Cystic Fibrosis.

Impact of CFTR Modulators on Beta-Cell Function in Children and Young Adults with Cystic Fibrosis.

Journal: Journal of clinical medicine

Published: May 16, 2022

Age at menarche in girls with cystic fibrosis and asthma.

Age at menarche in girls with cystic fibrosis and asthma.

Journal: Minerva endocrinology

Published: February 23, 2022

SARS-CoV-2 viral entry and replication is impaired in Cystic Fibrosis airways due to ACE2 downregulation.

SARS-CoV-2 viral entry and replication is impaired in Cystic Fibrosis airways due to ACE2 downregulation.

Journal: Nature communications

Published: November 09, 2021

Showing 1-12 of 22

Last Updated: 09/26/2026